This presentation, which the BMJ’s research editors Domhnall Macauley, Elizabeth Loder and Trish Groves have given at conferences around the world, explains how to get your research published. It includes clear guidelines on how to write a paper, clinical trial registration, ethics, authorship, conflicts of interest and how to navigate the peer review process.
Details
Interview with Dr John Cai, s a highly experienced economist and health economist with 20 years’ experience in both China and the US. John is a Senior Health Policy Analyst at the Massachusetts Executive Office of Health and Human Services in the U.S.
Details
The ISPOR 15th Annual European Congress Abstract Submission has opened today.
Taking place at the ICC Berlin, Germany ISPOR will be accepting abstract submissions which must be submitted through ISPOR’s online abstract system by June 26th 2012.
We asked Dr John Cai if the Chinese hospitals 15% mark up encourages use of expensive drugs? If so, how can we change this?
Details
Interview with Dr John Cai, a highly experienced economist and health economist with 20 years’ experience in both China and the US. John is a Senior Health Policy Analyst at the Massachusetts Executive Office of Health and Human Services in the U.S. heor.tv
Details
One of our Twitter followers @HealthEcoDigest recently blogged a podcast with the BMJ editor-in-chief Fiona Godlee and neuroscientist Professor Colin Blakemore. In the podcast, they are discussing whether a false…
Details
Medicine is not an exact science, so patients are left to understand its nuances without a basic primer in statistics. How do patients understand risk and make their health care decisions? Part of it involves delusion.
Details
heor.tv inteviewed Marilyn Dix Smith, Founding Executive Director of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and asked How was ISPOR founded and how much has it changed over the years?
Details
heor.tv inteviewed Marilyn Dix Smith, Founding Executive Director of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and asked about its impact on patient healthcare.
Details
‘Ghostwriting’ is a contentious issue among both medical practitioners and medical writers. Outside these circles, this issue typically only surfaces when either a politician decides to deplore it or a pharmaceutical company is implicated.
Details
